Erschienen in:
01.10.2014 | Original Article
The role of adjuvant chemotherapy in stage II colorectal cancer patients
verfasst von:
Hung-Hsin Lin, Yu-Yao Chang, Jen-Kou Lin, Jeng-Kai Jiang, Chun-Chi Lin, Yuan-Tzu Lan, Shung-Haur Yang, Huann-Sheng Wang, Wei-Shone Chen, Tzu-Chen Lin, Shih-Ching Chang
Erschienen in:
International Journal of Colorectal Disease
|
Ausgabe 10/2014
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Adjuvant chemotherapy use in stage II colorectal cancer (CRC) is debated. We evaluated the prognostic significance of clinicopathological features recommended by most guidelines for identifying high-risk stage II CRC and adjuvant chemotherapeutic response.
Methods
We enrolled 1,039 stage II CRC patients who underwent curative surgery at Taipei Veterans General Hospital from January 2005 to December 2010. Seventy-seven patients who received radiotherapy were excluded. The endpoint was disease-free survival.
Results
Of 962 patients, 37 had stage T4 tumors; 50, lymphovascular invasion; 39, poor differentiation; 249, preoperative carcinoembryonic antigen (CEA) levels >5 ng/mL; and 53 underwent emergent operations. One hundred ninety-four patients received 5-fluorouracil-based adjuvant chemotherapy. During a median follow-up period of 60.2 months, recurrence developed in 110 patients (11.4 %). The 5-year disease-free survival (DFS) was 87.6 %. In multivariate analysis, preoperative CEA >5 ng/ml (p = 0.001), emergent operation for obstruction/perforation (p = 0.008), lymphovascular invasion (p = 0.014), and T4 disease (p = 0.030) were significantly associated with poor DFS. High-risk stage II patients (n = 484) benefited from adjuvant chemotherapy (5-year DFS with and without adjuvant chemotherapy, 87.3 vs. 78.9 %; p = 0.028).
Conclusions
Adjuvant chemotherapy improved DFS in high-risk stage II CRC patients, but not in low-risk patients.